Summary
This international multicentre observational study of 686 patients with cardiogenic shock treated with VA-ECMO found that left ventricular unloading using an Impella device was associated with a 21% lower risk of 30-day mortality (hazard ratio 0.79, P=0.03) in a propensity score-matched cohort of 510 patients. Although left ventricular unloading reduced mortality, it was associated with higher complication rates including severe bleeding, access site ischaemia, and need for renal replacement therapy. The findings suggest potential clinical benefit of combined VA-ECMO and left ventricular unloading in cardiogenic shock management, though the mechanism and optimal patient selection remain uncertain.
UK applicability
These findings from 16 tertiary care centres across four countries are directly relevant to UK critical care practice, as VA-ECMO and Impella use in cardiogenic shock management would be considered at equivalent specialist centres in the NHS. UK adoption of these devices would benefit from confirmation through randomised trials, particularly given the increased complication burden.
Key measures
30-day mortality (hazard ratio); severe bleeding incidence; access site-related ischaemia; abdominal compartment syndrome; renal replacement therapy requirement
Outcomes reported
The study measured 30-day mortality rates and complication frequencies in cardiogenic shock patients treated with VA-ECMO, comparing those who received left ventricular unloading (via Impella device) with those who did not.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.